Active Endostatin (ES) Homo sapiens (Human) Active protein

Add to Cart Distributors
Overview
Properties
  • Buffer FormulationPBS, pH7.4, containing 5% Trehalose.
  • Traits Freeze-dried powder, Purity > 90%
  • Isoelectric Point9.1
Share your citation Upload your experimental result Review Leave a message
Loading...

Share a new citation as an author

Upload your experimental result

Review

Please attach serial No. on instruction manual

Contact us

Please fill in the blank.

Name*
Organization
Address
E-mail address*
Telephone
Inquiry*
Verification code* CheckCode
  • Active Endostatin (ES) Packages (Simulation)
  • Active Endostatin (ES) Packages (Simulation)
  • APA542Hu61.jpg Figure. SDS-PAGE
  • Certificate ISO9001: 2008, ISO13485: 2003 Registered

Activity test

Endostatin (ES) is a naturally occurring, 20kDa C-terminal fragment derived from type XVIII collagen. It is reported to serve as an anti-angiogenic agent, similar to angiostatin and thrombospondin. Endostatin is a broad-spectrum angiogenesis inhibitor and may interfere with the pro-angiogenic action of growth factors such as basic fibroblast growth factor (bFGF/FGF-2) and vascular endothelial growth factor (VEGF). To test the effect of ES on inhibit the VEGF basic-dependent proliferation of ECV304 endothelium cell line, cells were seeded into triplicate wells of 96-well plates at a density of 5, 000 cells/well when the cell attached, replaced with serum-free standard DMEM overnight. Then the medium was replaced with 2% serum standard DMEM which contain 10ng/mL of VEGFA and various concentrations of ES. After incubated for 72h, cells were observed by inverted microscope and cell proliferation was measured by Cell Counting Kit-8 (CCK-8). Briefly, 10µL of CCK-8 solution was added to each well of the plate, then measure the absorbance at 450nm using a microplate reader after incubating the plate for 1-4 hours at 37℃. The result was shown in Figure 1. It was obvious that ES (100ng/mL) significantly inhibit cell proliferation of EV304 cells.

Usage

Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.

Storage

Avoid repeated freeze/thaw cycles. Store at 2-8°C for one month. Aliquot and store at -80°C for 12 months.

Stability

The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37°C for 48h, and no obvious degradation and precipitation were observed. The loss rate is less than 5% within the expiration date under appropriate storage condition.

Citations

  • Endostatin gene therapy enhances the efficacy of IL-2 in suppressing metastatic renal cell carcinoma in miceSpringerLink: u38777121t6660l5
  • Erythrocyte Protoporphyrin Fluorescence as a Biomarker for Monitoring Antiangiogenic Cancer TherapySpringerLink: 4v306130302257w0
  • Endostatin- and interleukin-2-expressing retroviral bicistronic vector for gene therapy of metastatic renal cell carcinomaWiley: source
  • Endostatin neoadjuvant gene therapy extends survival in an orthotopic metastatic mouse model of renal cell carcinomaScienceDirect: S075333221100151X
  • Antiangiogenic Activities of Cinnamon, Black and Green Tea Extracts on Experimentally Induced Breast Cancer in RatsScialert: Source
  • Inflammation Induced by MMP-9 Enhances Tumor Regression of Experimental Breast CancerPubMed: PMC3619527
  • Promotion of adipogenesis by an EP2 receptor agonist via stimulation of angiogenesis in pulmonary emphysemaPubmed:24911647
  • Endostatin and kidney fibrosis in aging: a case for antagonistic pleiotropy?Source
  • Angiogenesis inhibitor endostatin protects mice with sepsis from multiple organ dysfunction syndromePubMed: 26125086
  • Endothelial Dysfunction and Nailfold Videocapillaroscopy Pattern as Predictors of Digital Ulcers in Systemic Sclerosis: a Cohort Study and Review of the LiteraturePubMed: 26142066
  • Peripheral vasculopathy in Raynaud phenomenon: Vascular disease biomarkersscience:S1646706X16300052
  • Impaired angiogenesis as a feature of digital ulcers in systemic sclerosisPubmed:26920752
  • Blood biomarker for early blood brain barrier disruption in ischemic strokepatent:US20170199205A1

Recommend products